 |
160 Products |  |
813 Diseases | | 160 Products |
|
1554 Trials |  |
75234 News |  |
| «12...6364656667686970717273...858859» |
- Blincyto (blinatumomab) / Astellas, Amgen
SHORT-TERM BLINATUMOMAB BRIDGING ALLO-HSCT IN HR B-ALL (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_869;
Busulfan/cyclophosphamide(BU/CY)-based myeloablative conditioning regimen will beperformed on the 15th day. Short-term BiTE brigding BUCY conditioning regimen could improve the OS of HR B-ALL compared with BUCYregimen, and was likely to lower the incidence of aGVHD.
- Blincyto (blinatumomab) / Astellas, Amgen
BLINATUMOMAB ALTERNATING WITH LOW-INTENSITY CHEMOTHERAPY (LIC) IN OLDER ADULTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): SAFETY RUN-IN FOLLOW-UP FOR THE PHASE 3 GOLDEN GATE STUDY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_862;
P3
Blinatumomab alternating with LIC demonstrated an acceptable safety profile and was efficacious in olderadults with newly diagnosed Ph-neg B-ALL. These data support the planned regimen for the randomized phaseof the study.
- Blincyto (blinatumomab) / Astellas, Amgen
ALLOGENEIC STEM CELL TRANSPLANTATION DOES NOT SUGGEST IMPROVING OVERALL SURVIVAL IN ADOLESCENT AND YOUNG ADULT WITH PHILADELPHIA CHROMOSOME ACUTE LYMPHOBLASTIC LEUKEMIA WITH UNDETECTABLE BCR::ABL1. (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_861;
In our multicenter real-world study, while we observe higher CR rates in AYA population, we did not observesignificant differences in MRD negative CR or uBCR::ABL1 at 3 mo from initiation of treatment between AYAand older pts group. Moreover, among AYA pts with uBCR::ABL1 at 3 mo, we did not observe an addedadvantage of allo-HCT in improving survival.
- Tecartus (brexucabtagene autoleucel) / Gilead
BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) AS CONSOLIDATION TREATMENT IN ADULTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH MARROW BLASTS <5%, INCLUDING PATIENTS (PTS) WITH NGS MRD NEGATIVE DISEASE (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_859;
We noted CART expansion in pts with no morphologic disease prior to LD. Prospective trials are planned to assess role of CART in low tumor burden setting, including MRD+ and as consolidation strategy.
- Blincyto (blinatumomab) / Astellas, Amgen
EFFICACY AND TOLERANCE OF MODIFIED HYPERCVAD, BLINATUMOMAB, AND TKI COMBINATION AS A TREATMENT FOR RELAPSED OR REFRACTORY PH+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_851;
These results suggest that the HyperCVAD-Blinatumomab-TKI combination (mostly ponatinib) achieves a highresponse rate (CR with negative MRD) in patients with Ph+ B-ALL R/R. However, cardio-vascular and infectiouscomplications temper these results and raise questions about the exact role of chemotherapy in this indication,especially for elderly patients.
- Blincyto (blinatumomab) / Astellas, Amgen
EFFICACY AND SAFETY ANALYSIS OF HYPER-CVAD AND SEQUENTIAL BLINATUMOMAB FOR ACUTE LYMPHOCYTIC LEUKEMIA AND CHRONIC MYELOID LEUKEMIA BLAST CRISIS PATIENTS (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_850;
We conducted a retrospective analysis of patients who had received one course of Vincristine and Prednisone(VP) based induction regimen and alternating blocks of Blinatumomab (9?g or 28?g/day by continuousintravenous infusion for 14 or 28 days according to patients situation) and intensive chemotherapy (hyper-CVAD [hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone] alternating withhigh-dose methotrexate and cytarabine) as consolidation regimen in Huazhong university of science andtechnology affiliated Union hospital between 2022 to 2024 (Figure 1). Blinatumomab combined with chemotherapy resulted in encouraging MRD response and long-term survival forALL and CML-BP patients in consolidation.
- Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
AUGMENTED USE OF L-ASPARAGINASE MARKEDLY IMPROVES THE TREATMENT RESULT OF AYA ALL PATIENTS: RESULT OF PROSPECTIVE MRD 2014 STUDY CONDUCTED BY FUKUOKA BLOOD AND MARROW TRANSPLANTATION GROUP (FBMTG) (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_846;
Notably, compared to MRD 2008 (UMIN000001519), the total dose of L-Asp has been raised from 36000 U/m2to 232000 U/m2 in patients aged 16-35, and from 36000 U/m2 to 132000 U/m2 in patients aged 36-65. Withthis modification, the treatment outcomes for patients aged 16-35 demonstrated remarkable improvement.
- Blincyto (blinatumomab) / Astellas, Amgen
BLINATUMOMAB INDUCTION THERAPY FOLLOWING REDUCED-DOSE CHEMOTHERAPY IN NEWLY DIAGNOSED ADULT PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA:MULTICENTRE, SINGLE ARM, PHASE 2 STUDY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_843;
P2
Withthis modification, the treatment outcomes for patients aged 16-35 demonstrated remarkable improvement. The induction treatment with RDC, consisted of one dose of idarubicin (8 mg/m2),one dose of vindesine (3 mg/m2, up to 4mg), and dexamethasone (9 mg/m2/day) for 7 days, followed by a 2-week course of blinatumomab (9
- Blincyto (blinatumomab) / Astellas, Amgen
SAFETY AND EFFICACY OF BLINATUMOMAB AS BRIDGING THERAPY IN PEDIATRIC B-ALL PATIENTS WITH CHEMOTHERAPY INTOLERANCE: A MULTICENTER RETROSPECTIVE ANALYSIS (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_841;
The induction treatment with RDC, consisted of one dose of idarubicin (8 mg/m2),one dose of vindesine (3 mg/m2, up to 4mg), and dexamethasone (9 mg/m2/day) for 7 days, followed by a 2-week course of blinatumomab (9 Blinatumomab is safe and effective in first-line treatment of chemotherapy-intolerant children withB-ALL.
- Blincyto (blinatumomab) / Astellas, Amgen
THE EFFICACY AND SAFETY OF SHORTEN PERIOD OF BINATUMOMAB AND SEQUENTIAL ALLO-HSCT IN RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTICENTER RETROSPECTIVE STUDY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_840;
The sequential allo-HSCT was seem to improve long termsurvival. Further large sample study and prospective clinical trail are needed to confirm our findings.
- Blincyto (blinatumomab) / Astellas, Amgen
EXPERIENCE WITH BLINATUMOMAB IN ADULTS WITH ACUTE B LYMPHOBLASTIC LEUKEMIA IN LATIN AMERICA: MULTICENTER RETROSPECTIVE STUDY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_836;
Adverse events were comparable to those reported inthe literature. Almost half of patients receiving blinatumomab were successfully bridged to allo-HCT.
- Blincyto (blinatumomab) / Astellas, Amgen
BLINATUMOMAB'S EFFECTIVENESS AND SAFETY IN ADOLESCENTS AND YOUNG ADULTS(AYA) PATIENTS WITH PHILADELPHIA-NEGATIVE B-ACUTE LYMPHOBLASTIC LEUKEMIA(ALL) AFTER INITIAL THERAPY: SINGLE-CENTER STUDY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_833;
Our results support the benefit of usingblinatumomab in upfront therapy of B-ALL with excellent OS and PFS. The toxicity of such approach ismanageable.
- Blincyto (blinatumomab) / Astellas, Amgen
IMPROVING OUTCOME IN ELDERLY PHILADELPHIA NEGATIVE ACUTE LIMPHOBLASTIC LEUKEMIA: FEASIBILITY AND EFFICACY OF AN INTENSIVE PEG-ASPARAGINASE-BASED REGIMEN (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_830;
Infections represent the leading cause of death in this fragile population. In this view the incorporation ofnovel targeted drugs may further improve the outcome.
- Venclexta (venetoclax) / Roche, AbbVie, Blincyto (blinatumomab) / Astellas, Amgen
THE FIRST RESULTS OF THE RALL-2016M PROTOCOL: "MRD-STATUS" BASED TARGET THERAPY FOR PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULT PATIENTS (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_829;
P=N/A
The results obtained both in terms of effectiveness and safety, namelythe absence of mortality both in induction and during consolidation, allow us to initiate this protocol as part ofa multicenter study. Continued research is needed to evaluate the long-term results of the therapy.
- ||||||| Ibrance (palbociclib) / Pfizer
Trial completion, Trial completion date, Trial primary completion date, Real-world evidence, Real-world: A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs (clinicaltrials.gov) - May 14, 2024
P=N/A, N=472, Completed, Sponsor: Pfizer
Continued research is needed to evaluate the long-term results of the therapy. Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Feb 2024 | Trial primary completion date: Jun 2024 --> Feb 2024
- ||||||| Ibrance (palbociclib) / Pfizer
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself. (clinicaltrials.gov) - May 14, 2024
P=N/A, N=779, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Feb 2024 | Trial primary completion date: Jun 2024 --> Feb 2024 Active, not recruiting --> Completed | Trial completion date: May 2024 --> Jan 2024 | Trial primary completion date: May 2024 --> Jan 2024
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
New P1 trial: Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder (clinicaltrials.gov) - May 14, 2024
P1, N=4, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Safety considerations in the treatment with anti-CGRP(R) monoclonal antibodies in patients with migraine. (Pubmed Central) - May 14, 2024
We observed CV events in 1.6% of patients with 1.5-year follow-up of anti-CGRP(R)-mAbs treatment. We advise awareness regarding CV events in patients with migraine undergoing CGRP-targeted treatment, not as a confirmation of increased risk but as a proactive measure to address potential multifactorial influences.
- | ivabradine / Generic mfg.
Journal: Intracardiac echocardiography guided anatomical ablation of the arcuate ridge for drug refractory inappropriate sinus tachycardia. (Pubmed Central) - May 14, 2024
We advise awareness regarding CV events in patients with migraine undergoing CGRP-targeted treatment, not as a confirmation of increased risk but as a proactive measure to address potential multifactorial influences. This is the first case series reporting the acute and long-term results of a novel anatomical approach for SN modulation to treat IST targeting the arcuate ridge
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
New P2 trial, Post-transplantation: MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure. (clinicaltrials.gov) - May 14, 2024
P2, N=60, Not yet recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
- Repatha (evolocumab) / Amgen, Astellas
Global burden of high-risk cardiovascular patients without prior myocardial infarction or stroke: VESALIUS-REAL - preliminary results from Germany (Station 10 - Research Gateway) - May 14, 2024 - Abstract #ESC2024ESC_6365;
P3
Despite having atherosclerosis and/or high-risk DM and LDL-C exceeding target thresholds, a large proportion of VESALIUS-CV like patients were not on any LLT in Germany. Final results from VESALIUS-REAL will be able to report if this treatment gap is also observed in other countries.
- nicorandil / Generic mfg., ivabradine / Generic mfg., ranolazine ER / Generic mfg.
Placebo-controlled efficacy of 17 anti-anginal drugs and percutaneous coronary intervention for first-line treatment of stable angina: systematic review & meta-analysis of 5153 patients from 53 trials (Station 3 - Research Gateway) - May 14, 2024 - Abstract #ESC2024ESC_5597;
The DHP CCB class showed the largest effect size, and ivabradine and ranolazine showed the smallest. The effect of PCI monotherapy was similar to the mean anti-anginal medication monotherapy effect.
- omecamtiv mecarbil (AMG 423) / Amgen, Servier
Menopausal status and clinical outcomes in women with heart failure with reduced ejection fraction: the GALACTIC-HF trial (Station 6 - Research Gateway) - May 14, 2024 - Abstract #ESC2024ESC_5404;
Additional research is necessary to understand how risk factors unique to females might influence outcomes in those with heart failure. The benefit of omecamtiv mecarbil on reducing cardiovascular risk was consistent regardless of menopausal status.
- Repatha (evolocumab) / Amgen, Astellas
Very short-term effects of single dose of proprotein convertase subtilisin kexin 9 inhibitor therapy before percutaneous coronary intervention (Station 7 - Research Gateway) - May 14, 2024 - Abstract #ESC2024ESC_5381;
Maximal lipid-core burden index over any 4-mm segment (max-LCBI4mm) and total lipid-core burden index (T-LCBI) at the target lesions were assessed with NIRS-IVUS and they were administered evolocumab 420mg... Single dose of PCSK9 inhibitor therapy before PCI resulted in significant degression of lipid core plaques identified by NIRS at the target lesion in very short period of time.
- Effects of lipid-lowering therapies on lipoprotein(a) levels in patients with dyslipidemia: a systematic review and network meta-analysis of 64 randomised controlled trials (Station 4 - Research Gateway) - May 14, 2024 - Abstract #ESC2024ESC_4203;
PCSK9 inhibitors produced the greatest effect on Lp(a) levels, compared with other lipid-lowering therapies. Further studies into PCSK9 inhibitors are necessary to characterise their efficacy and safety specifically for Lp(a)-lowering, and elucidate the impact of Lp(a) reduction on cardiovascular risk.
- Praluent (alirocumab) / Sanofi, Regeneron, Repatha (evolocumab) / Amgen, Astellas
Gender differences in the treatment with PCSK9 monoclonal antibodies real world experience from a dedicated prevention clinic (Station 4 - Research Gateway) - May 14, 2024 - Abstract #ESC2024ESC_3769;
In patients treated with PCSK9 mAb, gender differences exist in prescription age, indications, baseline LDL-C and achieved LDL-C goals. In this study adherence to PCSK9 mAb was higher than reported before, possibly due to surveillance in a dedicated prevention clinic.
- Praluent (alirocumab) / Sanofi, Regeneron, Repatha (evolocumab) / Amgen, Astellas
Sex dsparities in LDL-C and Non-HDLC response to PCSK9 Inhibitors (Station 6 - Research Gateway) - May 14, 2024 - Abstract #ESC2024ESC_2967;
Among all patients on PCSK9 inhibitors, both alirocumab and evolocumab showed a strong positive correlation with non-HDL-C and LDL-C level reduction at 6-months follow up, while at 12-months evolocumab had a better positive correlation. In addition, men on PCSK9I had a steeper decline in non-HDL-C and LDL-C levels at 6- and 12-months compared to women.
- Leqvio (inclisiran) / Novartis
Efficacy and safety of inclisiran in real-world clinical practice. Results from the CHOLINET Registry (Station 6 - Research Gateway) - May 14, 2024 - Abstract #ESC2024ESC_2966;
These preliminary data from the Cholinet Italian registry show that inclisiran effectively reduces (50%) LDL-C in real-world settings. The LDL-C target was achieved in 62% of patients; of them 91% were on lipid-lowering therapy, showing that combination therapy is necessary in most of these patients.
- ivabradine / Generic mfg.
Ivabradine prevents doxorubicin-induced cardiotoxicity via attenuating mitochondrial dysfunction and mitochondrial dynamic imbalance in H9C2 cells and rats (Station 2 - Research Gateway) - May 14, 2024 - Abstract #ESC2024ESC_2817;
IVA effectively protected against DOX-induced cardiotoxicity through improvement of mitochondrial function, mitochondrial dynamics, and reduction of oxidative stress. These findings suggest the therapeutic potential of IVA in preventing Dox-induced cardiotoxicity.
- ranolazine ER / Generic mfg.
Ranolazine therapy is associated with a reduced new diagnosis of diabetes mellitus in chronic coronary syndrome patients: the results of a real-world analysis of an Italian population (Station 3 - Research Gateway) - May 14, 2024 - Abstract #ESC2024ESC_2496;
Conclusions This real-world study, performed in a whole subset of the Italian population, showed that, in the long-term, the incidence of a new DM diagnosis was lower in Ran users. This association could contribute to explain the benefits of the drug in patients with CCS.
- Efficacy of lipid lowering therapy beyond statins to prevent cardiovascular events (Station 4 - Research Gateway) - May 14, 2024 - Abstract #ESC2024ESC_1408;
A potential survival benefit was also not observed in studies with follow-up duration of ? 3 years.
- digoxin / Generic mfg., ivabradine / Generic mfg.
20 year picture of a heart failure clinic: changes in the patients profiles' and 2-year mortality. (Station 2 - Research Gateway) - May 14, 2024 - Abstract #ESC2024ESC_443;
HFrEF remained the most common, but is declining in favour of HFpEF. Ischaemic aetiology also remained the most frequent but, again, showed a decreasing trend.
- Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Outcomes and effects of sacubitril/valsartan according to NT-proBNP level in patients with heart failure: a patient-level pooled analysis of the PARADIGM-HF and PARAGON-HF trials (Copenhagen) - May 14, 2024 - Abstract #ESC2024ESC_120;
Recently, it has been suggested that the effectiveness of certain treatments may vary by NT-proBNP level with greater benefit from omecamtiv mecarbil, and smaller benefit from vericiguat, in patients with higher NT-proBNP levels...Patients with LVEF ?40% were randomized to sacubitril/valsartan 200 mg twice daily or enalapril 10mg twice daily in PARADIGM-HF, and those with LVEF ?45% to sacubitril/valsartan 200 mg twice daily or valsartan 160mg twice daily in PARAGON-HF... Patients with higher NT-proBNP had worse outcomes, but the benefits of sacubitril valsartan were consistent across the range of NT-proBNP levels of participants in PARADIGM-HF and PARAGON-HF.
- Repatha (evolocumab) / Amgen, Astellas
Functional improvement of non-infarct related coronary artery stenosis by extensive LDL-C reduction with a PCSK9 antibody: the FITTER trial, microvascular function analysis (Station 3 - Research Gateway) - May 14, 2024 - Abstract #ESC2024ESC_46;
Participants were randomized and treated for 12 weeks with either evolocumab or placebo in addition to high-intensity statin therapy... The FITTER trial will provide new insights on the potential of extensive LDL-C reduction with a PCSK9 antibody on microvascular coronary artery function in patients presenting with ACS and MVD.
- ||| Biomarker, Enrollment change: BOUQUET: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (clinicaltrials.gov) - May 14, 2024
P2, N=176, Active, not recruiting, Sponsor: Hoffmann-La Roche
The FITTER trial will provide new insights on the potential of extensive LDL-C reduction with a PCSK9 antibody on microvascular coronary artery function in patients presenting with ACS and MVD. N=550 --> 176
- | Opdivo (nivolumab) / BMS, Vectibix (panitumumab) / Amgen, Yervoy (ipilimumab) / BMS
Trial completion date: PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC (clinicaltrials.gov) - May 13, 2024
P2, N=56, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
N=550 --> 176 Trial completion date: Mar 2024 --> Dec 2024
- || Darzalex (daratumumab) / J&J, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion date, Trial primary completion date: MUKnineb: MUK Nine b: OPTIMUM Treatment Protocol (clinicaltrials.gov) - May 13, 2024
P2, N=95, Active, not recruiting, Sponsor: University of Leeds
Trial completion date: Mar 2024 --> Dec 2024 Trial completion date: Jun 2023 --> May 2026 | Trial primary completion date: Dec 2022 --> Oct 2025
- | Prolia (denosumab) / Amgen
Enrollment closed: Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation (clinicaltrials.gov) - May 13, 2024
P=N/A, N=20, Active, not recruiting, Sponsor: University of Calgary
Trial completion date: Jun 2023 --> May 2026 | Trial primary completion date: Dec 2022 --> Oct 2025 Recruiting --> Active, not recruiting
- | Prolia (denosumab) / Amgen
Journal: Local radiographic risk factors for MRONJ in osteoporotic patients undergoing tooth extraction. (Pubmed Central) - May 13, 2024
Recruiting --> Active, not recruiting Tooth extraction sites showing radiographic signs of chronic dental infection are prone to MRONJ.
- | divarasib (RG6330) / Roche
Journal: Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC. (Pubmed Central) - May 13, 2024
Tooth extraction sites showing radiographic signs of chronic dental infection are prone to MRONJ. Although previously difficult to target, sotorasib and adagrasib are now approved for previously treated NSCLC patients with KRAS G12C mutations...While sotorasib met its primary endpoint
- || Enbrel (etanercept) / Pfizer, Amgen
Review, Journal: The Role of Etanercept in Controlling Clinical and Radiological Progression in Rheumatoid Arthritis: A Systematic Review. (Pubmed Central) - May 13, 2024
There was also concern about tuberculosis and malignancy, but no recent data is available. Therefore, a larger clinical trial with longer follow-up is required to ascertain long-term safety and benefits.
- | ivabradine / Generic mfg.
Journal: Effect of Ivabradine on Left Ventricular Reverse Remodeling in Relatively Stable Heart Failure Outpatients With Reduced Ejection Fraction. (Pubmed Central) - May 13, 2024
Therefore, a larger clinical trial with longer follow-up is required to ascertain long-term safety and benefits. Significant left ventricular reverse remodeling was observed 10.1
- || olpasiran (AMG 890) / Amgen
New P1 trial: A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants (clinicaltrials.gov) - May 12, 2024
P1, N=32, Not yet recruiting, Sponsor: Amgen
- | Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment closed: NCI-2017-00596: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 12, 2024
P2, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Significant left ventricular reverse remodeling was observed 10.1 Recruiting --> Active, not recruiting
- || Trial completion date, Trial primary completion date, IO biomarker: National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 12, 2024
P2, N=423, Active, not recruiting, Sponsor: University of Birmingham
Recruiting --> Active, not recruiting Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
- | Repatha (evolocumab) / Amgen, Astellas
Journal: Inhibition of PCSK9 with evolocumab modulates lipoproteins and monocyte activation in high-risk ASCVD subjects. (Pubmed Central) - May 12, 2024
Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024 This trial is the first to demonstrate that PCSK9 mAB with evolocumab can modulate circulating immune cell properties and highlights the importance of "stress" profiling of circulating immune cells that more clearly define immune contributions to ASCVD.
- || Review, Journal: Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence. (Pubmed Central) - May 12, 2024
Low doses, intermittent treatment may increase ADA formation. An appropriate biologic should be selected based on the ADA formation rate and course of treatment.
- | Blincyto (blinatumomab) / Astellas, Amgen
Biomarker, Review, Journal, Residual disease, Minimal residual disease: The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia. (Pubmed Central) - May 11, 2024
The introduction of targeted therapies (especially those targeting CD19, such as blinatumomab or CAR-T19) introduces several challenges for flow cytometric MRD analysis, such as the occurrence of CD19-negative relapses...(Semi-)automated MRD assessment, employing machine learning algorithms and clustering tools, shows promise but does not yet allow robust and sensitive automated analysis of MRD. Future directions involve integrating artificial intelligence, further automation, and exploring multicolor spectral flow cytometry to standardize MRD assessment and enhance diagnostic and prognostic robustness of MRD diagnostics in BCP-ALL.
- || Prolia (denosumab) / Amgen
Review, Journal: Links among Obesity, Type 2 Diabetes Mellitus, and Osteoporosis: Bone as a Target. (Pubmed Central) - May 11, 2024
Bisphosphonates and denosumab significantly reduced the risk of vertebral fractures in patients with both obesity and T2DM...It is important to recognize elevated fracture risk and osteoporosis in obese and T2DM patients, as they are currently considered low risk and tend to be underdiagnosed and undertreated. The implementation of better diagnostic tools, including trabecular bone score, lumbar spine BMD/body mass index (BMI) ratio, and microRNAs to predict bone fragility, could improve fracture prevention in this patient group.
- || Granocyte (lenograstim) / Roche, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Review, Journal: Balancing Benefits and Risks: A Literature Review on Hypersensitivity Reactions to Human G-CSF (Granulocyte Colony-Stimulating Factor). (Pubmed Central) - May 11, 2024
Immediate ones were mostly caused by filgrastim (13 minimum), with at least 9 being grade 5 on the WAO anaphylaxis scale...Only five desensitization protocols have been found concerning the topic at hand in the analyzed data. We believe this study brings to light the research interest in this topic that could benefit from further exploration, and propose regular updating to include the most recently published evidence.